Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

Your Advisors

Ernie Tremblay- Money Morning - Only the News You Can Profit From.

Ernie Tremblay has over 20 years' experience studying and writing about the latest developments in health, medicine, and related technologies. He understands the FDA approval process, the "hard science" behind these drugs, and the market demand for them, better than almost anyone else on earth. He has mastered the complex dynamics that determine whether a new drug will be a breakthrough winner - or just another casualty of the FDA approval process.

He has edited books on science, microbiology, and groundbreaking medical therapies for top publishers like Harper Collins, Penguin Putnam, and Prentice Hall. He's also co-authored and contributed to books and articles on diseases from Alzheimer's to rheumatology. Over the decades, Ernie has gained "insider" access to some of the world's top medical professionals, including Nobel-caliber doctors like Yale's Karel Liem, Columbia's George Gaylord Simpson, and Harvard's William S. Beck.

As a guest editor for Money Map Press since 2012, Ernie has already given readers opportunities to land substantial gains - including one bioscience stock that brought readers triple-digit gains four times in eight months. Now he's putting his developed knowledge of the inner workings of the FDA drug approval process to work for members of his BioScience Millionaire service, showing them precisely when a new drug or medical technology is about to give a calendar "pop" to a company's share price.